Literature DB >> 25450152

Interval debulking surgery following neo-adjuvant chemotherapy for stage IVB ovarian cancer using neutral argon plasma (PlasmaJet™).

Simon Butler-Manuel1, Jonathan Lippiatt2, Thumuluru Kavitha Madhuri1.   

Abstract

OBJECTIVE: We present a novel surgical approach to ovarian cancer debulking using neutral argon plasma (PlasmaJet™). CASE HISTORY: A 48 year-old woman diagnosed with FIGO stage IVB grade 3 serous epithelial ovarian carcinoma received three cycles of neoadjuvant chemotherapy with carboplatin and paclitaxel. OPERATIVE TECHNIQUE: Dissection and radical debulking surgery were performed using PlasmaJet™ as previously described [1,2]. This included diaphragmatic and abdominal peritoneal stripping, supra-colic omentectomy, tumour ablation on the small and large intestines and mesentery, pelvic and para-aortic lymphadenectomy.
RESULTS: The only post-operative complication was a superficial wound breakdown, which healed by secondary intention. She remains well two years after surgery, with no sign of recurrence.
CONCLUSION: In this case, PlasmaJet™ facilitated diaphragmatic peritoneal stripping as well as dissection of tissue close to bowel and major vessels. Further study is required to assess whether this device can reduce the need for bowel resection while achieving complete cytoreduction.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cytoreduction; Debulking; Lymphadenectomy; Ovarian; Plasma; Surgery

Mesh:

Substances:

Year:  2014        PMID: 25450152     DOI: 10.1016/j.ygyno.2014.09.007

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  4 in total

1.  A Comparison of Thermal Plasma Energy Versus Argon Beam Coagulator-Induced Intestinal Injury After Vaporization in a Porcine Model.

Authors:  Edward J Tanner; Erica Dun; Yukio Sonoda; Alexander B Olawaiye; Dennis S Chi
Journal:  Int J Gynecol Cancer       Date:  2017-01       Impact factor: 3.437

Review 2.  Appropriate Recommendations for Surgical Debulking in Stage IV Ovarian Cancer.

Authors:  Jing-Yi Chern; John P Curtin
Journal:  Curr Treat Options Oncol       Date:  2016-01

3.  Adjuvant Use of PlasmaJet Device During Cytoreductive Surgery for Advanced-Stage Ovarian Cancer: Results of the PlaComOv-study, a Randomized Controlled Trial in The Netherlands.

Authors:  G M Nieuwenhuyzen-de Boer; W Hofhuis; N Reesink-Peters; S Willemsen; I A Boere; I G Schoots; J M J Piek; L N Hofman; J J Beltman; W J van Driel; H M J Werner; A Baalbergen; A M L D van Haaften-de Jong; M Dorman; L Haans; I Nedelcu; P C Ewing-Graham; H J van Beekhuizen
Journal:  Ann Surg Oncol       Date:  2022-05-13       Impact factor: 4.339

Review 4.  Low temperature plasmas as emerging cancer therapeutics: the state of play and thoughts for the future.

Authors:  Adam M Hirst; Fiona M Frame; Manit Arya; Norman J Maitland; Deborah O'Connell
Journal:  Tumour Biol       Date:  2016-02-18
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.